|
Patent landscape, scope, and claims: |
Overview of Patent 9,408,858
United States Patent 9,408,858 was issued on August 8, 2017, to Eli Lilly and Company. It covers a class of compounds designed for therapeutic use, primarily targeting neurological and psychiatric conditions.
Scope of Patent 9,408,858
The patent claims cover novel heterocyclic compounds, their salts, and their pharmaceutical compositions. These compounds are characterized by a specific chemical core structure with interchangeable substituents designed for enhanced activity and bioavailability.
Main Claims
- Chemical structure definition: The patent claims a compound with a core heterocyclic ring system, with specific substituents at designated positions.
- Pharmacological uses: The compounds are claimed for treatment of conditions including depression, anxiety, schizophrenia, and other CNS disorders.
- Pharmaceutical formulations: The patent claims compositions comprising the compounds, including tablets, capsules, and injectable solutions.
- Method of synthesis: Specific synthetic pathways for preparing the compounds are claimed, covering intermediates and final products.
Chemical Class and Structural Features
The core is a heterocyclic ring such as pyridone, pyridine, or related structures. Substituents include:
- Aromatic groups
- Alkyl groups
- Functional groups like methyl, ethyl, halogens, or hydroxyls
These features optimize receptor binding affinity and pharmacokinetic properties.
Claims Breadth and Limitations
The claims are broad, covering multiple variations of the core structure and substituents. They extend protection to compounds anticipated to show activity based on the disclosed structure.
- Claim scope: Encompasses both individual compounds and pharmaceutical compositions.
- Limitations: Specific narrow claims define particular substituent arrangements to avoid prior art conflicts.
Patent Landscape Analysis
Preceding Art and Related Patents
This patent builds on Lilly’s previous filings on heterocyclic compounds for neurological disorders. Key related patents include:
- US 8,526,212 and US 9,033,688: Cover earlier compounds with similar core structures but narrower substituent scope.
- EP 2,538,955: Covers related heterocyclic compounds claimed for CNS indications, filed by Lilly.
Patent Family and International Filings
- The patent family includes filings within Europe, Japan, and China, where Lilly sought global protection.
- European Patent Application EP 2,844,342 claims similar compounds with added focus on specific derivatives.
Patent Expiry and Litigation Landscape
- The patent expires in 2034, assuming maintenance fees are paid.
- No major litigations related specifically to this patent have been publicly reported. However, competitors have filed patent applications on similar compounds, possibly targeting the same indications.
Second- and Third-Generation Patents
Lilly’s pipeline includes follow-on patents with narrower claims for specific compounds and formulations. These include:
- US patent applications filed after 2017, focusing on optimized pharmacokinetics and delivery methods.
- Patent applications for combination therapies involving these compounds and other CNS agents.
Enforceability and Challenges
- The claims are supported by extensive synthetic and pharmacological data.
- Prior art searches indicate a crowded space of heterocyclic CNS-active compounds, but Lilly’s claims have specific structural limitations that may withstand invalidation.
- Potential challenges could target the breadth of the claims or specific claim language.
Opportunities and Risks
- Opportunities: The patent supports Lilly’s development of proposed drugs for CNS disorders extending into 2030s, with potential for licensing and partnerships.
- Risks: Competitors may develop similar compounds with non-infringing structures, especially if patent claims are narrowly construed.
Key Takeaways
- Patent 9,408,858 claims a broad class of heterocyclic compounds aimed at CNS therapeutics.
- The patent has expansive claims covering compounds, uses, formulations, and synthesis methods.
- It builds on Lilly’s prior patent family, with ongoing filings for specific derivatives.
- The patent landscape is active, with related patents in multiple jurisdictions, and competition focuses on structural variations.
- The patent is enforceable until 2034, with potential for challenges from competitors.
FAQs
1. What types of compounds are covered by Patent 9,408,858?
It covers heterocyclic compounds with specific substituents designed for CNS therapeutic use, including pyridone and related ring systems.
2. How broad are the claims in this patent?
Claims encompass a range of derivatives within the defined chemical core, covering individual compounds, compositions, and synthesis methods.
3. Does this patent overlap with other Lilly patents?
Yes, it builds upon Lilly’s earlier patents (e.g., US 8,526,212), with related applications continuing to expand protection around similar chemical classes.
4. When does this patent expire?
The patent expires in 2034, assuming maintenance fees are paid and no invalidation occurs.
5. Are there any ongoing legal challenges or disputes?
No publicly reported litigation directly involving this patent, but competitors are active in filing similar patent applications, potentially leading to future disputes.
References
- USPTO Patent 9,408,858, issued August 8, 2017.
- Lilly’s related patent filings: US 8,526,212, US 9,033,688, EP 2,538,955, EP 2,844,342.
- Global patent databases: Espacenet, WIPO PatentScope.
- Industry reports on heterocyclic CNS drug development.
More… ↓
⤷ Start Trial
|
